H2020Индивидуална стипендия2019–2021

GLIOHAB · Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2019-06-01 → 2021-05-31
Финансиране от ЕС: 214 159 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Глиобластомата е агресивен тумор в мозъка, чиито различни клетки се анализират чрез нови методи за многопараметрично изображение. Това помага за по-точна прогноза и избор на персонализирано лечение за отделните пациенти.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation

Glioblastoma is the most frequent primary brain tumor. Glioblastoma has a poor prognosis, with an average survival of 14.6 months for patients undergoing Stupp standard treatment. Due to the extremely complex and heterogeneous molecular biology of glioblastoma “the same treatment for all” approach does not work well in this disease, and standard of care is not always the best option. Their intra-patient heterogeneity has been identified as one of the factors associated with its high aggressiveness, representing a key factor to understand tumor resistance against effective therapies. In this context, additional efforts are needed for generate novel strategies able to define more tailored personalized treatments that facilitate higher safety and efficacy for relevant sub-populations. GLIOHAB project has contributed to the characterization of the intra-patient heterogeneity of glioblastoma by developing new multi-parametric image analysis techniques and by applying them to improve prognosis estimation and patient follow-up.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Glioblastoma is not only the most frequent but also the most malignant tumour originating in the Central Nervous System. Due to the extremely complex and heterogeneous molecular biology of this tumour “the same treatment for all” approach does not work well in this disease, and standard of care is not always the best option. The intra-patient tumor heterogeneity is one of the responsible factors for the high aggressiveness of these lethal solid tumors and their resistance against effective therapies. In this context, additional efforts are needed for generate novel strategies able to define more tailored personalized treatments that facilitate higher safety and efficacy for relevant sub-populations.GLIOHAB project will develop an artificial intelligence based medical device able to monitor the functional state of the glioblastoma at pixel level. This software will be built on technologies previously co-developed, validated, and patented by the researcher. GLIOHAB will join best experts in the field, in a multidisciplinary and eminently clinical environment, which will provide the optimum conditions for a holistic approach to the solution. This proposal includes both the transfer of knowledge to the host institution and the training of the candidate in new advanced techniques. GLIOHAB results will contribute to monitor the response of highly aggressive tumours to complex treatments, and generate stratification strategies to select treatment responder patients.

Оригинален текст от CORDIS (на английски).

Участници

OSLO UNIVERSITETSSYKEHUS HF · OsloКоординаторНорвегия